Drug Profile
Gemigliptin/glimepiride - LG Chem
Alternative Names: Glimepiride/gemigliptin; ZemiSULatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in South Korea (PO, Tablet)
- 28 Aug 2015 Gemigliptin/glimepiride is still in phase I trials for Type-2 diabetes mellitus in South Korea
- 02 Apr 2014 LG Life Sciences plans a phase III trial for Type-2 diabetes mellitus in South Korea (NCT02089126)